These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38595921)

  • 1. Inhibition of ACOX1 enhances the therapeutic efficacy of obeticholic acid in treating non-alcoholic fatty liver disease and mitigates its lipotoxicity.
    Yang Y; Yuan W; He K; Lin C; Du S; Kou Y; Nie B
    Front Pharmacol; 2024; 15():1366479. PubMed ID: 38595921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice.
    Lin C; Yu B; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
    Front Pharmacol; 2022; 13():880508. PubMed ID: 35614939
    [No Abstract]   [Full Text] [Related]  

  • 3.
    Hu Y; Liu HX; Jena PK; Sheng L; Ali MR; Wan YY
    JHEP Rep; 2020 Apr; 2(2):100093. PubMed ID: 32195457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse.
    Lin C; Yu B; Liu X; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
    Biomed Pharmacother; 2022 Jun; 150():112984. PubMed ID: 35447541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease.
    Zhang DY; Zhu L; Liu HN; Tseng YJ; Weng SQ; Liu TT; Dong L; Shen XZ
    Drug Des Devel Ther; 2019; 13():2249-2270. PubMed ID: 31308634
    [No Abstract]   [Full Text] [Related]  

  • 6. Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis
    Li H; Xi Y; Liu H; Xin X
    Front Nutr; 2022; 9():914079. PubMed ID: 36091227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
    Yao J; Zhou CS; Ma X; Fu BQ; Tao LS; Chen M; Xu YP
    World J Gastroenterol; 2014 Oct; 20(39):14430-41. PubMed ID: 25339829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease.
    Gai Z; Gui T; Alecu I; Lone MA; Hornemann T; Chen Q; Visentin M; Hiller C; Hausler S; Kullak-Ublick GA
    Liver Int; 2020 Apr; 40(4):844-859. PubMed ID: 31883408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling.
    Zhai Y; Zhou W; Yan X; Qiao Y; Guan L; Zhang Z; Liu H; Jiang J; Liu J; Peng L
    Phytomedicine; 2022 Dec; 107():154444. PubMed ID: 36155217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in mice.
    de Oliveira MC; Gilglioni EH; de Boer BA; Runge JH; de Waart DR; Salgueiro CL; Ishii-Iwamoto EL; Oude Elferink RP; Gaemers IC
    Biochim Biophys Acta; 2016 Nov; 1862(11):2054-2062. PubMed ID: 27475255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesoid X receptor overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in nonalcoholic fatty liver disease.
    Xu S; Kong L; Li L; Wang C; Gu J; Luo H; Meng Q
    Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166930. PubMed ID: 37918680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator.
    Shiragannavar VD; Sannappa Gowda NG; Puttahanumantharayappa LD; Karunakara SH; Bhat S; Prasad SK; Kumar DP; Santhekadur PK
    Front Pharmacol; 2023; 14():1135952. PubMed ID: 36909161
    [No Abstract]   [Full Text] [Related]  

  • 13. Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice.
    Gu M; Zhao P; Zhang S; Fan S; Yang L; Tong Q; Ji G; Huang C
    Br J Pharmacol; 2019 Apr; 176(7):847-863. PubMed ID: 30635917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR/miR-34a/SIRT1 regulatory loop.
    Kong M; Peng Y; Qiu L
    Acta Biomater; 2023 Jul; 164():435-446. PubMed ID: 37040811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-222 targets ACOX1, promotes triglyceride accumulation in hepatocytes.
    Wang JJ; Zhang YT; Tseng YJ; Zhang J
    Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):360-365. PubMed ID: 31126802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
    Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
    Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.
    McGettigan BM; McMahan RH; Luo Y; Wang XX; Orlicky DJ; Porsche C; Levi M; Rosen HR
    J Biol Chem; 2016 Oct; 291(44):23058-23067. PubMed ID: 27605663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARĪ± is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD.
    Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y
    J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
    Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S
    Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shenge Formula attenuates high-fat diet-induced obesity and fatty liver via inhibiting ACOX1.
    Shang Z; Gao Y; Xue Y; Zhang C; Qiu J; Qian Y; Fang M; Zhang X; Sun X; Kong X; Gao Y
    Phytomedicine; 2024 Jan; 123():155183. PubMed ID: 37992491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.